Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.33 |
| ▸ | CHRNB4 known ✓ | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA7 known ✓ | P36544 | 1/20 | 0.32 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CTSC | P53634 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PEPD | P12955 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12773357 | 0.98 | BACE1 (0.44) | BACE1KMT2ACTSCCYP1A2ALOX15 | |
| SCHEMBL22490451 | 0.98 | BACE1 (0.44) | BACE1KMT2ACTSCCYP1A2ALOX15 | |
| Hydrochloric Acid SCHEMBL30759300 | 0.93 | BACE1 (0.42) | BACE1KMT2ACTSCCYP1A2ALOX15 | |
| Hydrochloric Acid SCHEMBL31656498 | 0.91 | BACE1 (0.41) | BACE1KMT2ACTSCCYP1A2ALOX15 | |
| SCHEMBL24112563 | 0.91 | BACE1 (0.43) | BACE1KMT2ACTSCCYP1A2ALOX15 | |
| SCHEMBL19318720 | 0.91 | BACE1 (0.43) | BACE1KMT2ACTSCCYP1A2ALOX15 | |
| SCHEMBL23824307 | 0.89 | BACE1 (0.42) | BACE1KMT2ACTSCCYP1A2ALOX15 | |
| SCHEMBL25922433 | 0.89 | BACE1 (0.42) | BACE1KMT2ACTSCCYP1A2ALOX15 | |
| SCHEMBL17811563 | 0.89 | BACE1 (0.39) | BACE1KMT2ACTSCCYP1A2ALOX15 | |
| Hydrochloric Acid SCHEMBL31656505 | 0.89 | BACE1 (0.39) | BACE1KMT2ACYP1A2ALOX15KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606634-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate which binds caludin-6 and claudin-9 | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-04-21 | — | — | US | disclosed |
| US-12350344-B2 | Methods of treating a tumor by administering a claudin-6 (CLDN6) or CLDN9 antibody-pyrrolobenzodiazepine derivative conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-07-08 | — | — | US | disclosed |
| US-20250114647-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING SUBSTITUTED BENZO[e]PYRROLO[1,2-a][1,4]DIAZEPINES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-04-10 | — | — | US | disclosed |
| US-12246196-B2 | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-03-11 | — | — | US | disclosed |
| US-20240299573-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-09-12 | — | — | US | disclosed |
| CN-117205296-A | Protease inhibition compound and application of composition thereof in preparation of cat infectious peritonitis medicines | 嘉兴安谛康生物科技有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-116763898-A | Application of protease inhibitor compound in preparation of cat coronavirus infection medicines | 北京科翔中升医药科技有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-114426568-B | 2-oxo-3-pyrrolidinyl propionitrile compounds, pharmaceutical composition and application thereof | 嘉兴安谛康生物科技有限公司 | 2023-04-25 | — | — | CN | disclosed |
| US-11628223-B2 | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-α][1,4]diazepines | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-04-18 | — | — | US | disclosed |
| US-20230084707-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-03-16 | — | — | US | disclosed |
| US-11583590-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-02-21 | — | — | US | disclosed |
| CN-115583984-A | Azaspiro compound and preparation method, pharmaceutical composition and application thereof | 嘉兴安谛康生物科技有限公司 | 2023-01-10 | — | — | CN | disclosed |
| US-20220395579-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-12-15 | — | — | US | disclosed |
| CN-115385983-A | Azabicyclo compound, preparation method, pharmaceutical composition and application thereof | 嘉兴安谛康生物科技有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-20220177601-A1 | ANTI-HER2 ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-06-09 | — | — | US | disclosed |
| US-20220168440-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DEPRIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-06-02 | — | — | US | disclosed |
| US-20220168438-A1 | COMBINATION OF ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE AND PARP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-06-02 | — | — | US | disclosed |
| CN-114426568-A | 2-oxo-3-pyrrolidinylpropionitrile compound, and pharmaceutical composition and application thereof | 安帝康（无锡）生物科技有限公司 | 2022-05-03 | — | — | CN | disclosed |
| CN-109705191-B | IAP inhibitors and their use in medicine | 广东东阳光药业有限公司 | 2022-04-29 | — | — | CN | disclosed |
| US-20220125943-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606634-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate which binds caludin-6 and claudin-9 | SIGLEC9, DSG1, VSIG8 | GAA 3533/4885CHRNB4 287/4885CHRNA3 41/4885 |
| US-20220168440-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DEPRIVATIVE CONJUGATE | CD79B, BTD, PDCD1 | GAA 1376/4885CHRNB4 1913/4885CHRNA3 1550/4885 |
| US-20240299573-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | PDCD6, EPCAM, CNTN1 | GAA 4485/4885CHRNB4 327/4885CHRNA3 124/4885 |
| US-11628223-B2 | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-α][1,4]diazepines | GABRA1, GABRA4, GABRA2 | GAA 2158/4885CHRNB4 624/4885CHRNA3 454/4885 |
| US-12350344-B2 | Methods of treating a tumor by administering a claudin-6 (CLDN6) or CLDN9 antibody-pyrrolobenzodiazepine derivative conjugate | EPCAM, PDCD6, JUP | GAA 3598/4885CHRNB4 1073/4885CHRNA3 883/4885 |
| US-20220168438-A1 | COMBINATION OF ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE AND PARP INHIBITOR | PARP2, PARP3, PARP1 | GAA 3952/4885CHRNB4 2818/4885CHRNA3 1399/4885 |
| US-20220125943-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | PDCD6, EPCAM, CNTN1 | GAA 4485/4885CHRNB4 327/4885CHRNA3 124/4885 |
| US-12246196-B2 | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines | CNTN1, BTN3A1, FABP6 | GAA 2919/4885CHRNB4 732/4885CHRNA3 596/4885 |
| US-20230084707-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | PDCD6, EPCAM, CNTN1 | GAA 4485/4885CHRNB4 327/4885CHRNA3 124/4885 |
| US-20250114647-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING SUBSTITUTED BENZO[e]PYRROLO[1,2-a][1,4]DIAZEPINES | CNTN1, BTN3A1, FABP6 | GAA 2909/4885CHRNB4 742/4885CHRNA3 608/4885 |
| US-11583590-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor | EPCAM, PDCD6, CNTN1 | GAA 3931/4885CHRNB4 676/4885CHRNA3 436/4885 |
| US-20220177601-A1 | ANTI-HER2 ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | ERBB2, BRD2, PA2G4 | GAA 1330/4885CHRNB4 3001/4885CHRNA3 2519/4885 |
| US-20220395579-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | PDCD6, EPCAM, CNTN1 | GAA 4485/4885CHRNB4 327/4885CHRNA3 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.